Novo-Nordisk ADR repsg 1 B Ord Shs NVO

Healthcare Biotechnology

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

NYSE:NVO - Post by User

Novo-Nordisk ADR repsg 1 B Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by Trader19Swifton Dec 02, 2024 10:56am

33 Views

Post# 36340750

Novo Nordisk: Big Pharma’s Next Crown Jewel?

Potential Medicare and Medicaid coverage expansion for anti-obesity drugs could be a game-changer. I'm bullish on NVO's long-term prospects. Similarly, MYNZ's developments are paving the way for future growth."

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week